Haleon plc Reports Share Transaction Activity
Ticker: HLNCF · Form: 6-K · Filed: Sep 30, 2025 · CIK: 1900304
Sentiment: neutral
Topics: share-transaction, disclosure, capital-allocation
TL;DR
Haleon bought/sold its own shares in Sept 2025 - check the 6-K for details.
AI Summary
Haleon plc filed a Form 6-K on September 30, 2025, reporting a transaction in its own shares. The filing details activities related to the company's share repurchases or issuances during the month of September 2025.
Why It Matters
This filing provides insight into Haleon's capital allocation strategy and its ongoing management of its share capital.
Risk Assessment
Risk Level: low — The filing is a routine disclosure of share transactions and does not indicate any immediate financial distress or significant operational changes.
Key Players & Entities
- Haleon plc (company) — Registrant
- DRVW 2022 Ltd (company) — Former name of registrant
- September 2025 (date) — Reporting period for share transactions
FAQ
What specific type of transaction in own shares did Haleon plc conduct?
The filing, Exhibit 99.1, is titled 'Transaction in Own Shares' and pertains to activities during September 2025, but the specific details of the transaction (e.g., buyback, issuance) are not elaborated in the provided text.
What is the reporting period for this Form 6-K?
The report is for the month of September 2025, with the filing date as of September 30, 2025.
What is Haleon plc's principal executive office address?
Haleon plc's principal executive offices are located at Building 5, First Floor, The Heights, Weybridge, Surrey, KT13 0NY.
Has Haleon plc filed or will it file annual reports under Form 20-F or Form 40-F?
Yes, Haleon plc indicates it files annual reports under Form 20-F.
What was Haleon plc's former name?
Haleon plc's former name was DRVW 2022 Ltd, with a date of name change on December 17, 2021.
Filing Stats: 589 words · 2 min read · ~2 pages · Grade level 11 · Accepted 2025-09-30 07:21:28
Filing Documents
- a2997b.htm (6-K) — 33KB
- a2997b000.jpg (GRAPHIC) — 3KB
- 0001654954-25-011209.txt ( ) — 39KB
From the Filing
IN OWN SHARES a2997b UNITED STATES   SECURITIES AND EXCHANGE COMMISSION   Washington, D.C. 20549     FORM 6-K   REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934   For the month of September 2025   Commission File Number: 001-41411   Haleon plc (Translation of registrant’s name into English)   Building 5, First Floor, The Heights, Weybridge, Surrey, KT13 0NY (Address of principal executive offices)     Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:     Form 20-F ☒   Form 40-F ☐                  EXHIBIT INDEX   Exhibit Number Description 99.1 30 September 2025 - “Transaction in Own Shares”         99.1     Haleon plc:   Transaction in own shares   30 September 2025:   Haleon plc (the "Company" or "Haleon") today announces   the purchase of 1,996,340 ordinary shares of £0.01 each in the Company (the "Shares")   under the second tranche of its share buyback programme announced on 31 July 2025.     London Stock Exchange CBOE (UK)/BXE CBOE (UK)/CXE Date of purchase: 29 September 2025 29 September 2025 29 September 2025 Number of Shares purchased: 1,996,340 - - Highest price paid per Share (p): 331.6000 - - Lowest price paid per Share (p): 328.7000 - - Volume weighted average price paid per Share (p): 330.3042 - -   The Company intends to hold the purchased shares as treasury shares.   Following the settlement of the above, the Company's registered share capital   is 8,952,353,648 ordinary shares of £0.01 each, of which 42,900,783 are held as treasury shares.   Therefore, the number of ordinary shares with voting rights is 8,909,452,865 and   this figure may be used by shareholders to determine if they are required to notify their interest, or a change to their interest, in Haleon under the FCA's Disclosure Guidance and Transparency Rules.   In accordance with Article 5(1)(b) of Regulation (EU) No 596/2014 as it applies in the UK (the Market Abuse Regulation), a full breakdown of the individual trades is available at the link below:   http://www.rns-pdf.londonstockexchange.com/rns/2957B_1-2025-9-29.pdf   This announcement does not constitute, or form part of, an offer or any solicitation of an offer for securities in any jurisdiction.   This announcement and individual trade breakdown will also be available on the Company's website at:   www.haleon.com/investors .   Enquiries     Investors Media   Jo Russell   +44 7787 392441 Zo ë   Bird +44 7736 746167 Rakesh Patel      +44 7552 484646 Victoria Durman +44 7894 505730 Email:   investor-relations@haleon.com Email:   corporate.media@haleon.com   About Haleon Haleon (LSE/NYSE: HLN) is a global leader in consumer health, with a purpose to deliver better everyday health with humanity. Haleon's product portfolio spans six major categories - Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin Health and Other. Its long-standing brands - such as  Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu  and  Voltaren  - are built on trusted science, innovation and deep human understanding.   For more information, please visit   www.haleon.com .        SIGNATURE       Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.       HALEON PLC (Registrant)   Date : September 30, 2025 By: /s/ Amanda Mellor     Name: Amanda Mellor     Title: Company Secretary